VVOS Vivos Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VVOS

Price (delayed)

$2.63

Market cap

$7.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$11.14

Enterprise value

$7.54M

Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA). Vivos believes that ...

Highlights
VVOS's EPS has soared by 57% YoY and by 14% from the previous quarter
The net income has grown by 43% YoY and by 12% from the previous quarter
The company's quick ratio has shrunk by 57% YoY but it rose by 47% QoQ
The equity has dropped by 91% year-on-year
The gross profit has declined by 17% year-on-year and by 5% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.vivoslife.com
Peers: NVRO OFIX NURO

Key stats

What are the main financial stats of VVOS
Market
Shares outstanding
2.73M
Market cap
$7.18M
Enterprise value
$7.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.66
Price to sales (P/S)
0.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.55
Earnings
Revenue
$13.8M
EBIT
-$13.58M
EBITDA
-$12.96M
Free cash flow
-$12.8M
Per share
EPS
-$11.14
Free cash flow per share
-$10.5
Book value per share
$0.34
Revenue per share
$11.32
TBVPS
$6.12
Balance sheet
Total assets
$10.73M
Total liabilities
$10.32M
Debt
$2M
Equity
$411,000
Working capital
-$4.83M
Liquidity
Debt to equity
4.85
Current ratio
0.34
Quick ratio
0.25
Net debt/EBITDA
-0.03
Margins
EBITDA margin
-93.9%
Gross margin
59.9%
Net margin
-98.4%
Operating margin
-125.3%
Efficiency
Return on assets
-104.7%
Return on equity
-568.6%
Return on invested capital
-1,871.6%
Return on capital employed
-394.7%
Return on sales
-98.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VVOS stock price

How has the Vivos Therapeutics stock price performed over time
Intraday
1.15%
1 week
2.33%
1 month
-12.62%
1 year
-67.11%
YTD
-78.86%
QTD
-45.55%

Financial performance

How have Vivos Therapeutics's revenue and profit performed over time
Revenue
$13.8M
Gross profit
$8.27M
Operating income
-$17.3M
Net income
-$13.58M
Gross margin
59.9%
Net margin
-98.4%
The net income has grown by 43% YoY and by 12% from the previous quarter
Vivos Therapeutics's net margin has increased by 34% YoY and by 7% from the previous quarter
Vivos Therapeutics's operating income has increased by 31% YoY and by 10% from the previous quarter
The company's operating margin rose by 20% YoY and by 5% QoQ

Growth

What is Vivos Therapeutics's growth rate over time

Valuation

What is Vivos Therapeutics stock price valuation
P/E
N/A
P/B
7.66
P/S
0.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.55
VVOS's EPS has soared by 57% YoY and by 14% from the previous quarter
The equity has dropped by 91% year-on-year
The price to book (P/B) is 82% lower than the last 4 quarters average of 42.5
VVOS's P/S is 71% below its last 4 quarters average of 0.8
Vivos Therapeutics's revenue has decreased by 14% YoY and by 4.8% from the previous quarter

Efficiency

How efficient is Vivos Therapeutics business performance
The return on invested capital has dropped by 53% since the previous quarter
VVOS's ROS is up by 34% YoY and by 7% from the previous quarter
The company's return on equity fell by 29% QoQ
The company's return on assets rose by 7% QoQ and by 6% YoY

Dividends

What is VVOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VVOS.

Financial health

How did Vivos Therapeutics financials performed over time
VVOS's total assets is 4% higher than its total liabilities
The current ratio has dropped by 58% year-on-year but it is up by 21% since the previous quarter
The company's quick ratio has shrunk by 57% YoY but it rose by 47% QoQ
The equity has dropped by 91% year-on-year
VVOS's debt to equity has dropped by 89% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.